EAH.L Stock Analysis
EA
Neutral
Based on Eyestock quantitative analysis, EAH.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
0.098
Dividend yield
0.31 %
Shares outstanding
67.722 B
ECO Animal Health Group Plc engages in the development, registration and marketing of pharmaceutical products for animals. The company is headquartered in New Malden, Surrey and currently employs 221 full-time employees. The Company’s patented drug, Aivlosin, is a macrolide antibiotic for treatment of respiratory and enteric diseases in pigs and poultry. The Company’s generic drugs include Ecomectin, Ecoheart, Ecotraz and Ecomintic, which are endectocides and other antiparasitic. Its generic drugs are developed for the treatment and prevention of parasites in cattle, sheep, pigs, horses and dogs. The Company’s Chlortetracycline and Oxytetracycline are developed for the treatment of bacterial infections in pigs, poultry and cattle. The Company’s segment includes the United Kingdom, China and Japan, North America, South and South East Asia, Latin America, Europe, and the Rest of the World.